As of the latest Form 4 filed Jun 22, 2026.
What Travere Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 67 most recent filings for TVTX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | 2026-06-22 | Inrig Jula CHIEF MEDICAL OFFICER | GGift | −468.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Baynes Roy D. Director | SSale | −4.50K | $50.00 | $225K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Baynes Roy D., Director | MExercise | +4.50K | $21.38 | $96.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Coughlin Timothy Director | SSale | −10.0K | $50.07 | $501K | Yes (planned) | Form 4 ↗ |
| 2026-06-16 | 2026-06-12 | Coughlin Timothy, Director | MExercise | +10.0K | $26.52 | $265K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-06 | Cline Christopher R. CHIEF FINANCIAL OFFICER | SSale | −310.00 | $43.95 | $13.6K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-06 | Inrig Jula CHIEF MEDICAL OFFICER | SSale | −311.00 | $43.95 | $13.7K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-06 | Dube Eric M CHIEF EXECUTIVE OFFICER | SSale | −22.5K | $43.95 | $989K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-06 | ROTE WILLIAM E. Chief Research Officer | SSale | −2.76K | $43.95 | $121K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-06 | REED ELIZABETH E Chief Legal Officer and GC | SSale | −2.08K | $43.95 | $91.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | Cline Christopher R. CHIEF FINANCIAL OFFICER | SSale | −2.18K | $46.65 | $102K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | Inrig Jula CHIEF MEDICAL OFFICER | SSale | −2.17K | $46.65 | $101K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | Heerma Peter CHIEF COMMERCIAL OFFICER | SSale | −2.17K | $46.65 | $101K | No | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | Baynes Roy D. Director | SSale | −4.50K | $46.65 | $210K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | Baynes Roy D., Director | MExercise | +4.50K | $18.27 | $82.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-05 | REED ELIZABETH E Chief Legal Officer and GC | SSale | −2.17K | $46.65 | $101K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | MExercise | +4.25K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Inrig Jula CHIEF MEDICAL OFFICER | MExercise | +4.25K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Inrig Jula, CHIEF MEDICAL OFFICER | SSale | −20.0K | $45.00 | $900K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Inrig Jula, CHIEF MEDICAL OFFICER | MExercise | +20.0K | $22.40 | $448K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Heerma Peter CHIEF COMMERCIAL OFFICER | MExercise | +4.25K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Dube Eric M CHIEF EXECUTIVE OFFICER | MExercise | +22.5K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | ROTE WILLIAM E. Chief Research Officer | MExercise | +4.25K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Meckler Jeffrey A Director | SSale | −8.00K | $45.00 | $360K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Meckler Jeffrey A, Director | MExercise | +8.00K | $16.33 | $131K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | REED ELIZABETH E Chief Legal Officer and GC | MExercise | +4.25K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | REED ELIZABETH E, Chief Legal Officer and GC | SSale | −20.0K | $45.00 | $900K | Yes (planned) | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | REED ELIZABETH E, Chief Legal Officer and GC | MExercise | +20.0K | $17.96 | $359K | Yes (planned) | Form 4 ↗ |
| 2026-04-23 | 2026-04-22 | ROTE WILLIAM E. Chief Research Officer | SSale | −9.10K | $39.09 | $356K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | SSale | −22.0K | $41.07 | $903K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER | MExercise | +6.50K | $20.46 | $133K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER | MExercise | +6.25K | $8.93 | $55.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER | MExercise | +2.50K | $22.40 | $56.0K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D. Director | SSale | −6.75K | $42.12 | $284K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | SSale | −26.0K | $41.07 | $1.07M | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | MExercise | +6.75K | $17.11 | $115K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | MExercise | +4.50K | $21.38 | $96.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | MExercise | +4.50K | $18.27 | $82.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | MExercise | +9.00K | $15.43 | $139K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Baynes Roy D., Director | MExercise | +8.00K | $17.94 | $144K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | LYONS GARY A Director | SSale | −8.00K | $41.07 | $329K | Yes (planned) | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | LYONS GARY A, Director | MExercise | +8.00K | $16.33 | $131K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | SSale | −1.01K | $42.61 | $43.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Inrig Jula CHIEF MEDICAL OFFICER | SSale | −1.02K | $42.61 | $43.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | SSale | −20.00 | $42.66 | $853.20 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Dube Eric M, CHIEF EXECUTIVE OFFICER | SSale | −7.17K | $41.75 | $299K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Dube Eric M, CHIEF EXECUTIVE OFFICER | SSale | −56.8K | $41.01 | $2.33M | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | REED ELIZABETH E Chief Legal Officer and GC | SSale | −1.56K | $42.53 | $66.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | REED ELIZABETH E, Chief Legal Officer and GC | SSale | −5.23K | $41.62 | $218K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Cline Christopher R. CHIEF FINANCIAL OFFICER | SSale | −7.24K | $41.93 | $304K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Cline Christopher R., CHIEF FINANCIAL OFFICER | SSale | −9.00 | $41.07 | $369.63 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Inrig Jula CHIEF MEDICAL OFFICER | SSale | −7.21K | $41.93 | $303K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Heerma Peter CHIEF COMMERCIAL OFFICER | SSale | −7.21K | $41.93 | $303K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | SSale | −7.21K | $41.93 | $303K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | REED ELIZABETH E, Chief Legal Officer and GC | SSale | −37.5K | $41.07 | $1.54M | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | REED ELIZABETH E, Chief Legal Officer and GC | MExercise | +7.50K | $15.46 | $116K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | REED ELIZABETH E, Chief Legal Officer and GC | MExercise | +20.0K | $17.96 | $359K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | REED ELIZABETH E, Chief Legal Officer and GC | MExercise | +10.0K | $19.08 | $191K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Cline Christopher R. CHIEF FINANCIAL OFFICER | SSale | −65.00 | $28.85 | $1.88K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Cline Christopher R., CHIEF FINANCIAL OFFICER | AAward | +14.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Inrig Jula CHIEF MEDICAL OFFICER | AAward | +14.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Heerma Peter CHIEF COMMERCIAL OFFICER | AAward | +14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Dube Eric M CHIEF EXECUTIVE OFFICER | AAward | +64.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | ROTE WILLIAM E. Chief Research Officer | AAward | +14.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | REED ELIZABETH E Chief Legal Officer and GC | AAward | +14.0K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-04-07 | 2026-04-06 | Baynes Roy D. Director | SSale | −10.0K | $33.00 | $330K | Yes (planned) | Form 4 ↗ |
| 2026-04-07 | 2026-04-06 | Baynes Roy D., Director | MExercise | +10.0K | $26.52 | $265K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TVTX’s full analysis or the market-wide insider trading feed. The tabs above jump to TVTX’s other SEC data.
Source: SEC Form 4 filings for TVTX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.